Critical Analysis of the Claims and US Patent Landscape for US 10,071,108

US 10,071,108 claims methods for treating chronic hepatitis B virus (HBV) infection by administering an FXR (farnesoid X receptor) agonist, including selective FXR agonists and specific compound exemplars. The claim set is built around three pillars: (i) therapeutic use of FXR agonists in chronic HBV, (ii) narrowing to FXR selectivity and specific chemical identities, and (iii) patient and regimen tailoring (genotype A-D, prior non-response, and combination with existing HBV standards of care).

What do the claims actually cover?

Independent method concept

The independent claim theme has two variants:

Claim 1 (treatment): administering a therapeutically effective amount of an FXR agonist to treat chronic HBV infection.
Claim 9 (biomarker effect): administering a therapeutically effective amount of an FXR agonist to reduce HBsAg and/or HBeAG synthesis and/or secretion and/or reduce serum HBV DNA.

These two claim families are functionally the same technology premise but written as either a clinical treatment method (claim 1) or a measurable virology/antigen endpoint method (claim 9). This matters for freedom-to-operate (FTO) because accused products can be argued into either theory based on study endpoints and labeling language.

Claim narrowing layers

The dependent claims narrow along three axes:

HBV genotype
- Claims 2 and 10 limit the subject to HBV genotypes A, B, C, and D.
FXR pharmacology
- Claims 3 and 11 require the FXR agonist to be selective FXR agonist.
Specific FXR agonist exemplars / identity by CAS
- Claims 4 and 12 define an allowed set by CAS identifiers and named examples.
- Claims 5 and 13 narrow that set further to CAS 1192171-69-9 and 6ECDCA.
- The inclusion of GW4064, PXL0914, PXL0743 in the multi-compound dependent claims signals that the patent drafter intended to anchor protection around known FXR agonist chemotypes as well as proprietary/less-public compounds.
Prior therapy failure and combination regimens
- Claims 6-8 and 14-16:
  - require failed response to previous HBV therapy (claim 6/14),
  - list conventional agents: lamivudine, adefovir, tenofovir, telbivudine, entecavir and interferon alpha-2a / PEGylated forms, and
  - claim combination co-administration with those same agents (claim 8/16).

Claim set map (scope snapshot)

Claim group	Core limitation	Effect
1, 9	Administer FXR agonist to treat chronic HBV	Broad method utility covering any dosing that is “therapeutically effective”
2, 10	HBV genotype A-D	Moderate narrowing; still covers major clinical genotypes
3, 11	FXR agonist is “selective”	Narrows out non-selective or multi-receptor bile acid receptor agonists
4, 12	FXR agonist limited to CAS 1192171-69-9, 6ECDCA, GW4064, PXL0914, PXL0743	Converts broad biology claim into a chemical-identity claim subset
5, 13	FXR agonist limited to CAS 1192171-69-9 and 6ECDCA	Tightest identity anchor
6, 14	Subject failed to respond to prior HBV treatment	Narrows to treatment-resistant population
7, 15	Prior treatment enumerated (NAs + interferons)	Makes “failure” tethered to named standards
8, 16	FXR agonist in combination with named therapies	Protects add-on regimens

Which claims are strongest for infringement and which are vulnerable?

Strongest: identity-anchored dependent claims

In enforcement, the best targets are claims with fixed chemical identities because accused products can be matched directly.

Claims 4 and 12 are strong if the competitor’s HBV FXR agonist aligns with any of:
- CAS 1192171-69-9, 6ECDCA, GW4064, PXL0914, PXL0743.
Claims 5 and 13 are strongest (tightest) because they restrict to:
- CAS 1192171-69-9 and 6ECDCA.

If an accused FXR agonist is a structural variant, prodrug, salt form, or formulation of one of the specified CAS identities, enforcement arguments can still be built depending on how the patent defines “compound” (not provided in your excerpt). But at minimum, the identity-by-CAS language supports a clean claim chart.

Moderate: “selective FXR agonist” dependent claims

Claims 3 and 11 narrow to “selective FXR agonist.”
This is enforceable if the accused compound’s receptor profile can be demonstrated via assay data or regulatory pharmacology.

The vulnerability is that “selective” can become litigated as a definitional question: selectivity can be scalar (EC50 ratio, panel outcomes) and may be sensitive to assay conditions. Without the patent’s definitional language (not supplied here), this category can be harder to enforce purely on identity.

Broadest: independent treatment and biomarker-effect claims

Claim 1 and Claim 9 are broad because they cover any FXR agonist that is “therapeutically effective,” but those claims are also the ones most exposed to:
- novelty/obviousness attacks (if FXR agonists were previously reported for HBV endpoints),
- non-infringement arguments (if a competitor’s mechanism is debated, or if they do not achieve claimed endpoints in a way that maps to “reducing synthesis/secretion” or “therapeutically effective amount” in the claim construction).

From a litigation perspective, broad independent claims are often harder for the patent owner to prove on a clean record because they invite mechanism and outcome disputes.

Narrow but practical: genotype A-D and prior non-response

Claims 2 and 10 (genotype A-D) are narrow but clinically relevant. A genotype-based limitation can help novelty while still capturing the majority of common real-world HBV.
Claims 6-8 and 14-16 (prior non-response and combination with specified standards) are enforceable only if:
- the treated subject is in fact “failed to respond” under a recognized prior regimen, and
- the accused product label or real-world usage supports combination co-administration timing and regimen design.

Those claims can be commercially meaningful because real-world HBV treatment often involves switching or add-on strategies after NA or interferon failure.

What is the likely patent landscape around FXR agonists in HBV?

How this patent positions in the broader HBV pharmacology field

US 10,071,108 sits at the intersection of:

nuclear receptor modulation (FXR agonism),
HBV biology (HBsAg, HBeAG, and HBV DNA reduction),
and antiviral treatment sequencing.

In patent-landscape terms, the main competitive threat usually comes from prior art that discloses:

FXR agonists as antivirals or antigen suppressors in HBV models or patients, and/or
methods of reducing HBsAg/HBeAG via FXR engagement, and/or
known FXR agonist molecules used for HBV endpoints, and/or
combination regimens with standard of care nucleos(t)ide analogs or interferons.

Your excerpt shows the patent anticipates these threats by embedding known FXR agonists (GW4064) and related chemotypes (PXL0914, PXL0743) inside dependent claims. That is a sign the applicant wanted to preserve at least partial claim coverage even if earlier broad FXR-HBV disclosures existed.

Landscape implications by claim type

Landscape risk area	How the US 10,071,108 claims respond
Prior disclosure of FXR agonists reducing HBV markers	Independent claims broaden; dependent identity-by-CAS aims to preserve enforceability for specific molecules
Prior disclosure of general bile acid receptor modulation	“Selective FXR agonist” narrows receptor specificity
Prior disclosure of known FXR agonists	Dependent claims name GW4064 and the PXL series; identity claims help avoid full invalidation of the entire method family
Combination with nucleoside analogs or interferons	Combination dependent claims tie add-on use to specific listed comparators

Where competitors likely focus

A competitor seeking to reduce infringement exposure would typically:

avoid FXR agonists that match the specified CAS identities (if the product is in that space),
avoid combination regimens that look like the listed combination claims, or
use dosing/treatment design that is not claimed (for example, not targeting failed responders, or not producing the claimed biomarker effects in a measurable way).

However, if the competitor’s drug is itself one of the specified FXR agonists, the chemical-identity-dependent claims become hard to avoid.

What are the commercial and regulatory stakes of these claims?

Clinical endpoints and fit with registrational strategy

Claim 9 aligns directly with common HBV clinical surrogate endpoints:

HBsAg
HBeAG
HBV DNA

This linkage matters because many HBV development programs use these endpoints in trial readouts. A development strategy that demonstrates these reductions can be used by the patent owner to argue literal or at least practical coverage under the biomarker-based claim.

Selectivity and mechanism proof

Claim 3/11 require “selective FXR agonist.” This pushes evidentiary burdens toward:

receptor binding data,
functional activation assays,
and selectivity panels.

A competitor’s mechanistic package (including off-target nuclear receptor activity) can determine whether it fits the “selective FXR agonist” limitation.

Treatment sequencing

Claims 6-8 and 14-16 matter operationally in HBV:

“Failed to respond” to NAs and/or interferons is a common clinical subgroup.
add-on approaches are common after monotherapy failure.

That makes the claims potentially actionable beyond de novo therapy and into real-world treatment pathways.

Critical evaluation: internal coherence and enforceability constraints

Coherence of “reducing synthesis/secretion”

Claim 9 requires reduction in HBsAg and/or HBeAG “synthesis and/or secretion.” That is a mechanistic phrasing that can become a construction battle:

If the clinical evidence only measures serum concentrations without directly demonstrating synthesis vs secretion, the patent owner may still argue that reductions necessarily reflect downstream effects consistent with the claim.
A competitor can attack by arguing the evidence is not mechanistic enough and only supports indirect changes.

In practice, HBV trials measure serum antigen levels. The claim’s mechanistic phrasing increases litigation risk for both sides.

“Therapeutically effective amount”

Claim 1 and claim 9 both use “therapeutically effective amount,” a broad standard. This often increases flexibility for the patent owner but also invites:

disputes about dose-response mapping,
and disputes about what qualifies as “effective” for chronic HBV in a clinically meaningful way.

Identity-based dependent claims can partially mitigate that risk, because dosing can be anchored to specific molecules in trial protocols.

Genotype limitation scope

Genotype A-D includes common clinical genotypes, but some patients have genotype E through H. Limiting to A-D narrows coverage and creates an avoidance route for products developed or labeled for non-A-D genotypes only. In HBV, however, the majority of prevalence is A-D, so the limitation remains commercially significant.

Combination dependent claims and real-world usage

Claims 8 and 16 cover combination with listed therapies. The enforceability depends on whether the accused regimen is truly a combination in the sense contemplated by the claims (timing, concurrent administration, and treatment intent). Competitors can sometimes reduce exposure by:

adopting sequential switching rather than co-administration, or
using different comparator drugs not listed in the claims.

But the listed comparators are a large subset of standard-of-care.

Key landscape conclusion

US 10,071,108 is structured to preserve enforceable coverage by mixing broad method-of-treatment claims with narrower dependent claims anchored on:

FXR selectivity, and
identity-by-CAS and known FXR agonists (GW4064, PXL0914, PXL0743),
plus pragmatic subgroup and regimen limitations (genotypes A-D, prior non-response, combinations with standard HBV agents).

If a competitor develops an HBV therapy using an FXR agonist that falls within the enumerated CAS set, the patent landscape risk rises sharply, because dependent claims provide cleaner claim charts than the broad independent claims.

Key Takeaways

The patent’s core scope is FXR agonist therapy for chronic HBV, with a second prong tied to HBsAg/HBeAG and/or HBV DNA reduction.
The most enforceable coverage likely comes from CAS-identified FXR agonists in claims 4, 5, 12, 13, followed by “selective FXR agonist” limitations in claims 3 and 11.
Genotype A-D and “failed prior treatment” create practical but non-exhaustive subgroup coverage; combination claims 8 and 16 can matter for real-world HBV sequencing.
Landscape risk for competitors is highest when their FXR agonist matches the enumerated chemical identities or is used as an add-on to the listed standard HBV therapies.

FAQs

1) What does US 10,071,108 primarily protect?

A method of treating chronic HBV in a subject by administering an FXR agonist, including methods aimed at reducing HBsAg/HBeAG and/or HBV DNA (claims 1 and 9), plus narrowed versions by genotype, selectivity, compound identity, prior non-response, and combination regimens.

2) Which dependent claims narrow the technology the most?

The narrowest molecule-identifying claims are claims 5 and 13, which limit the FXR agonist to CAS 1192171-69-9 and 6ECDCA. The multi-identity set in claims 4 and 12 is broader but still chemically anchored.

3) Do the claims cover all HBV genotypes?

No. The genotype limitation is limited to genotypes A, B, C, and D in claims 2 and 10.

4) Are combination therapies covered?

Yes. Claims 8 and 16 cover administration of the FXR agonist in combination with lamivudine, adefovir, tenofovir, telbivudine, entecavir, interferon alpha-2a, PEGylated interferon alpha-2a, and interferon alpha-2b.

5) What HBV endpoints are explicitly claimed?

Claims 9 focuses on reducing HBsAg and/or HBeAG synthesis and/or secretion and/or serum HBV DNA.

References

[1] United States Patent and Trademark Office (USPTO). US Patent 10,071,108.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	October 16, 2002	10,071,108	2038-02-19
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	January 07, 2004	10,071,108	2038-02-19
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	September 29, 2011	10,071,108	2038-02-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,071,108

Summary for Patent: 10,071,108